Telix Pharmaceuticals Limited (TLX) Income Statement
TLX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTLX revenue and net income
Where TLX's revenue goes
2025Each bar shows an amount and its share of revenue. TLX kept −0.9% of revenue as net income.
TLX profit margins
TLX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +652.9% | +513.8% | +473.0% | — |
| Gross profit | +574.5% | +485.5% | +404.9% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TLX quarterly EPS vs estimates
Telix Pharmaceuticals beat the analyst EPS estimate in 1 of the last 3 quarters.
TLX income statement
| 2025 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $160.1M | $7.6M | $5.2M | $3.5M | $195,142 | $31.8M | $29.4M | $32.3M |
| Cost of revenue | $565.2M | $65.2M | $38.7M | $2.0M | $15.4M | $16.1M | $3,793 | $21.4M | $24.9M |
| Gross profit | $640.2M | $94.9M | $5.0M | $3.2M | −$11.9M | $195,142 | −$3,793 | $8.1M | $7.5M |
| Research & development | $256.8M | $57.9M | $34.1M | $23.1M | $21.2M | $18.7M | $3.0M | $10,000 | $62,000 |
| Sales, general & admin | $356.8M | $87.1M | $41.1M | $18.0M | $11.3M | $9.1M | $2.7M | $20,000 | $54,000 |
| Total operating expenses | $613.6M | $186.9M | $53.3M | $29.0M | $28.4M | $27.8M | $6.5M | $30,000 | $116,000 |
| Operating income | $26.6M | −$91.9M | −$81.2M | −$44.2M | −$36.0M | −$29.3M | −$6.5M | −$30,000 | −$116,000 |
| Interest income | $5.8M | $1,000 | — | $67,000 | — | — | — | — | — |
| Interest expense | $55.1M | $406,000 | $195,683 | $1.2M | $2.4M | $29,018 | $9,401 | $518,962 | $419,641 |
| Income before taxes | −$7.9M | −$98.6M | −$99.0M | −$60.3M | −$31.1M | −$15.7M | −$6.4M | −$44,000 | −$132,000 |
| Income taxes | $2.8M | $5.5M | −$18.5M | −$15.4M | −$3.3M | −$1.9M | $9,401 | −$91,582 | $31,542 |
| Net income | −$10.7M | −$104.1M | −$80.5M | −$44.9M | −$27.9M | −$13.8M | −$6.4M | −$44,000 | −$132,000 |
| EBITDA | $79.8M | −$92.8M | −$70.1M | −$44.9M | −$24.5M | −$27.6M | −$6.8M | −$14,000 | −$16,000 |
| EPS (diluted) | $0.05 | −$0.33 | −$0.28 | −$0.17 | −$0.11 | −$0.07 | −$0.03 | $0.00 | $0.00 |
| Gross margin | 53.1% | 59.3% | 66.5% | 61.2% | −340.7% | 100.0% | −0.0% | 27.4% | 23.1% |
| Operating margin | 2.2% | −57.4% | −1,069.6% | −847.7% | −1,033.6% | −15,016.1% | −20.5% | −0.1% | −0.4% |
| Net margin | −0.9% | −65.0% | −1,059.9% | −861.1% | −799.6% | −7,087.1% | −20.1% | −0.1% | −0.4% |
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Jun '24 | Dec '23 | Jun '23 | Dec '22 | Jun '22 | Dec '21 | Jun '21 | Dec '20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $691.4M | $620.4M | $593.1M | $594.2M | $189.0M | $281.7M | $220.8M | $136.0M | $24.0M | $4.7M | $2.9M | $3.6M |
| Cost of revenue | $334.7M | $293.0M | $304.8M | $208.4M | $65.1M | $57.7M | $130.0M | $91.2M | $39.6M | $23.5M | $14.1M | $11.9M |
| Gross profit | $356.6M | $327.4M | $288.3M | $385.8M | $123.9M | $224.0M | $90.8M | $44.9M | −$15.6M | −$18.9M | −$11.2M | −$8.3M |
| Research & development | $179.3M | $134.6M | $124.0M | $75.2M | $45.8M | $98.4M | $30.4M | $33.0M | $24.8M | $20.5M | $13.7M | $14.5M |
| Sales, general & admin | — | — | $146.9M | $111.8M | $58.0M | $69.8M | $28.9M | $36.4M | $23.1M | $10.6M | $6.8M | $15.3M |
| Total operating expenses | $376.5M | $317.6M | $272.6M | $317.4M | $110.1M | $203.9M | $59.4M | $54.6M | $47.9M | $31.1M | $20.4M | $20.9M |
| Operating income | −$19.9M | $9.8M | $15.8M | $68.4M | $13.8M | −$15.6M | $31.4M | −$9.7M | −$63.5M | −$49.9M | −$31.6M | −$29.1M |
| Interest expense | $7.0M | $11.7M | $3.9M | $16.5M | $4.9M | $548,000 | $442,000 | $268,000 | $138,000 | $104,000 | $85,000 | $940,000 |
| Income before taxes | $42.4M | −$645,299 | −$7.3M | $46.9M | $9.1M | $15.4M | −$12.3M | −$27.9M | −$70.7M | −$62.0M | −$37.0M | −$35.2M |
| Income taxes | −$13.2M | $6.6M | −$3.9M | $8.7M | −$2.5M | −$4.1M | $2.0M | $5.3M | $188,000 | −$14.0M | −$4.5M | −$8.6M |
| Net income | $55.5M | −$7.3M | −$3.5M | $38.2M | $11.7M | $19.5M | −$14.3M | −$33.2M | −$70.9M | −$48.0M | −$32.5M | −$26.6M |
| EBITDA | $17.3M | $28.9M | $14.3M | $82.8M | $40.3M | $23.0M | −$8.6M | −$25.0M | −$67.8M | −$59.3M | −$33.9M | −$31.7M |
| EPS (diluted) | — | $0.04 | $0.01 | $0.06 | — | — | — | — | — | — | — | — |
| Gross margin | 51.6% | 52.8% | 48.6% | 64.9% | 65.6% | 79.5% | 41.1% | 33.0% | −64.8% | −402.4% | −384.1% | −228.9% |
| Operating margin | −2.9% | 1.6% | 2.7% | 11.5% | 7.3% | −5.5% | 14.2% | −7.1% | −264.0% | −1,065.2% | −1,085.9% | −808.2% |
| Net margin | 8.0% | −1.2% | −0.6% | 6.4% | 6.2% | 6.9% | −6.5% | −24.4% | −294.8% | −1,024.2% | −1,117.3% | −737.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TLX's financial statements (latest annual report filed February 20, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TLX financial results
In fiscal year 2025 (ended December 31, 2025), Telix Pharmaceuticals reported revenue of $1.2 billion, up 652.9% from the year before. It had a net loss of $10.7 million, a net profit margin of −0.9%. Diluted earnings per share came to $0.05. Over five years revenue grew at an average rate of 473.0% a year.
See the TLX stock overview for the latest quote and news, or the TLX chart for price history and technical indicators.
TLX income statement FAQ
What is Telix Pharmaceuticals's annual revenue?
Telix Pharmaceuticals reported total revenue of $1.2 billion for fiscal year 2025, which ended on December 31, 2025. That was up 652.9% from $160.1 million the previous year.
Is Telix Pharmaceuticals profitable?
No. Telix Pharmaceuticals reported a net loss of $10.7 million in fiscal 2025, a net profit margin of −0.9%; its operating margin was 2.2%.
What is Telix Pharmaceuticals's gross margin?
Telix Pharmaceuticals's gross margin was 53.1% in fiscal 2025: for every $100 of revenue, Telix Pharmaceuticals kept $53 after the direct cost of its products and services.
How much does Telix Pharmaceuticals spend on research and development?
Telix Pharmaceuticals spent $256.8 million on research and development in fiscal 2025, 21.3% of revenue.
How fast is Telix Pharmaceuticals growing?
Revenue grew 473.0% a year on average over the last five fiscal years, from $0.2 million to $1.2 billion.
What are Telix Pharmaceuticals's earnings per share?
Telix Pharmaceuticals earned $0.05 per diluted share in fiscal 2025, compared with $-0.33 a year earlier.
When does Telix Pharmaceuticals's fiscal year end?
Telix Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 20, 2026.